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Purpose: To report our short-term experience with bevacizumab in neovascular age-related 
macular degeneration (AMD) and recommend a new treatment strategy.
Methods:  Retrospective chart review of 29 consecutive patients receiving 1.25 mg of intra-
vitreal bevacizumab for AMD and completing 12 weeks of follow up. Outcome measures were 
best corrected visual acuity (BCVA) and optical coherence tomography (OCT) central macular 
thickness. Injections were repeated if no further improvement was observed.
Results: Twenty-nine eyes of 29 patients were included. The average BCVA improved from 
20/148 at baseline to 20/106 at twelve weeks (P = 0.041). Of the 29 eyes, 25 (86.2%) had stable 
or improved BCVA. Average mean central macular thickness measured by OCT improved from 
351 µm at baseline to 278 µm at 12 weeks (P = 0.003). Stabilization of vision and improved 
OCT central macular thickness were maintained for at least eight weeks following only a single 
injection in the majority of eyes. During the three months of follow up, only five eyes (17.2%) 
required repeat injections, with only three (10.3%) requiring retreatment at eight weeks and 
none at four weeks. No significant ocular or systemic side effects were observed.
Conclusion: This short-term data suggests that bevacizumab appears to be a safe and effec-
tive treatment for neovascular AMD. Injections as frequent as every month do not appear to 
be necessary since initial treatment effect appears to be maintained for at least eight weeks in 
almost all of our patients.
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Background
Antivascular endothelial growth factor (VEGF) therapy has been recently established 
as an effective treatment for subfoveal neovascular age-related macular degeneration 
(AMD). Two anti-VEGF agents, pegaptanib1 (Macugen; Eyetech Pharmaceuticals, Inc., 
New York, NY) and ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA) 
have been demonstrated to be effective in treating neovascular AMD. Bevacizumab 
(Avastin®, Genentech), a humanized monoclonal VEGF antibody derived from the 
same murine monoclonal antibody as ranibizumab, is approved for intravenous use in 
the management of colorectal cancer.2 Bevacizumab was initially used via intravenous 
injection in the management of AMD-related choroidal neovascularization (CNV).3 
Given the potential systemic thromboembolic side effects associated with the intrave-
nous use of bevacizumab,4 ophthalmologists have more recently been administering 
the medication via intravitreal injection in neovascular AMD. Several laboratory5–8 
and clinical9–14 studies have supported the short-term safety and efficacy of intravitreal 
bevacizumab. However, the long term effects, the optimal dose, and the best treatment Clinical Ophthalmology 2010:4
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regimen have not been clarified. We report our short-term 
experience with intravitreal bevacizumab in the treatment of 
AMD-related subfoveal CNV , and based on these findings, 
suggest that a treatment interval of greater than one month 
may be sufficient.
Methods
Twenty-nine consecutive patients with subfoveal CNV 
due to neovascular AMD who completed three months of 
  follow-up were included in the study. Intravitreal injection 
of bevacizumab was performed either as salvage or as pri-
mary therapy after all other treatment options were discussed. 
The Institutional Review Board (IRB) at the University of 
Virginia approved this retrospective chart review.
All included patients received 1.25 mg of intravitreal 
bevacizumab (0.05 mL of the aliquoted commercial solution 
of Avastin®) following a complete ocular evaluation, which 
included best-corrected Snellen visual acuity (BCVA), com-
plete ocular examination, fluorescein angiography (FA), and 
optical coherence tomography (OCT Stratus, Model number 
3000; Carl Zeiss Ophthalmic Systems, Dublin, CA, USA). 
Patients with a history of hypertension and thromboembolic 
events were not automatically excluded, since intravitreal 
administration of bevacizumab has not been shown to be 
unsafe in this population. Based on individual physician 
practices, patients were reevaluated at about two, four, eight, 
and 12 weeks following treatment. Moreover, ocular imaging 
with FA and OCT was not routinely performed at each follow 
up visit; however, OCT imaging was done for all included 
patients at presentation and at 12 weeks following initiation 
of treatment. Injections were repeated only if worsening or 
no further improvement in BCVA, macular edema, subretinal 
fluid, and/or pigment epithelial detachment was observed 
later during follow up after an initial favorable functional 
and/or anatomical response. Other forms of treatment were 
considered at the clinician’s discretion in eyes with no mea-
surable response or worsening after bevacizumab.
Best-corrected Snellen acuity was converted into 
  logarithm of the minimum angle of resolution (logMAR) 
for statistical analysis. Mean visual acuity and OCT central 
macular thickness at baseline and each follow up visit were 
compared using a Student’s t-test to determine statistical 
significance with 95% confidence intervals (P  0.05).
Results
Out of the 29 patients included in the study, 21 were females. 
The age ranged from 62 to 89 years (mean, 77.7 years). 
All treated eyes completed 12 weeks of follow up. Visual 
acuity and OCT data were available for all eyes at baseline 
and at 12 weeks follow up. The two-, four-, and eight-week 
data were available for 65.5%, 55.2%, and 55.2% of eyes, 
respectively. Of all 29 eyes, 20 (69.0%) had received prior 
treatments, 17 (58.6%) photodynamic therapy, five (17.2%) 
laser photocoagulation, one (3.4%) intravitreal triamcino-
lone, and one (3.4%) intravitreal pegaptanib.
The average BCVA improved from 20/148 at baseline to 
20/106 at 12-week follow-up (P = 0.041). Twenty-five eyes 
(86.2%) had stable or improved BCVA (Figure 1) and nine 
eyes (31.0%) ended up with 20/50 vision or better. Eighteen 
(62.1%) and 11 (37.9%) eyes experienced at least one and 
two lines of vision improvement, respectively. Only four 
eyes had worse BCVA at 12 weeks compared to baseline. 
Improvement in average visual acuity occurred over the first 
four weeks of follow up (P = 0.006), after which a trend 
towards stabilization was observed (Figure 2).
Average mean central macular thickness measured 
by OCT improved from 351 µm at baseline to 278 µm 
at 12 weeks (P = 0.003). Twenty-four eyes (82.8%) had 
improved central macular thickness (Figure 3) and 15 eyes 
(51.7%) had less than 250 microns central macular thick-
ness by 12 weeks (Figure 4). The majority of the change 
in average central macular thickness was observed over 
the first two weeks following treatment (P = 0.0001) and 
improvement was maintained through the 12-week follow-
up visit (Figure 5). Worsening in average central macular 
thickness was observed at the four-week visit compared to 
the two-week visit but this was not associated with worsen-
ing in average BCVA. Twelve eyes had FA at the 12-week 
follow-up visit. Out of those, nine eyes (75%) had stable 
or less leakage compared to baseline, out of which six eyes 
(66.7%) had less leakage.
During the three months follow up, fewer than a fifth 
of the eyes (five eyes, 17.2%) required repeat injections, 
with only three eyes (10.3%) requiring retreatment at eight 
weeks and none at four weeks. No ocular or systemic side 
effects were observed, although patients were not specifi-
cally monitored for variations in their blood pressure during 
follow up.
Conclusion
Most eyes treated with bevacizumab in this study had a 
favorable anatomical and functional response, and 62.1% 
had improved BCVA by at least one line. As in previous 
studies,9,11–13 BCVA and central macular thickness as mea-
sured by OCT were stabilized or improved in the majority 
of eyes (86.2% and 82.8% respectively; Figures 1 and 3). Clinical Ophthalmology 2010:4
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Figure 1 Change in visual acuity 12 weeks after initial treatment with bevacizumab (scatter plot).
Note: All dots below the line indicate eyes with improved vision.
Abbreviation: LogMAR, logarithm of the minimal angle of resolution.
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Figure 2 Change in average best-corrected Snellen visual acuity (VA) over time following initial treatment with bevacizumab.
Notes: The majority of the change occurred in the first 4 weeks following treatment with stabilization afterwards. P values at each follow up visit were obtained by comparing 
with baseline (P value less than 0.05 indicates statistical significance).Clinical Ophthalmology 2010:4
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Most of the change in BCVA and central OCT thickness was 
observed in the first month and first two weeks following 
initial treatment respectively (Figures 2 and 5). However, 
the treatment regimen used in this study differs from previ-
ous studies in that patients were not routinely treated on a 
monthly basis for the first three months in a manner similar 
to the ranibizumab studies. In the series reported by Bashshur 
and colleagues13 and Avery and colleagues,9 all eyes received 
monthly bevacizumab for the first three months. Moreover, 
Spaide and colleagues11 reported that “patients were treated 
with the thought that they would be given three injections 
separated by one month and then followed until leakage 
reoccurred.” But no further details regarding the number 
of eyes reinjected as a function of time were reported. On 
the other hand, Rich and colleagues12 reported that “while 
reinjections were at the discretion of the treating physician, 
most patients were treated until the OCT revealed no evidence 
of macular fluid and then retreated when the fluid recurred.” 
In this study, because we wished to minimize the ‘off-label’ 
use of an unproven agent, injections were repeated only if 
we felt that the effects of the injection were ‘wearing off’, 
as indicated by no further improvement or worsening later 
during follow up after an initial favorable functional and/or 
anatomical response.
While it remains unknown how best to treat patients with 
intravitreal anti-VEGF therapy, particularly bevacizumab, we 
believe that fixed interval regimens used in previous studies 
may interfere with the ability to understand the pharmaco-
kinetic properties of this drug. This also does not allow for 
establishing the optimal frequency of reinjection. Treating on 
a monthly basis for the first three months9,13 or until the OCT 
reveals no evidence of macular fluid12 obscures the duration 
of effect of each injection and result in excessive number of 
injections that may be unnecessary. This likely explains why 
55% of eyes reported by Rich and colleagues12 (and 100% of 
eyes reported by Avery and colleagues9 and Bashshur and col-
leagues)13 required retreatment after one month from initial 
injection compared to our study, where less than a fifth of 
the eyes (17.2%) required repeat injections during the three 
months follow up. In this study, eyes that showed initial OCT 
improvement were not retreated even if the OCT disclosed 
residual macular fluid. The presence of residual fluid may not 
necessarily mean that retreatment is indicated. Residual fluid 
may still indicate “less” fluid, which still suggests a good, 
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Figure 3 Change in average central macular thickness (CMT) as measured by optical coherence tomography (OCT) 12 weeks after initial treatment with bevacizumab 
  (scatter plot).
Note: All dots below the line indicate eyes with reduced CMT.Clinical Ophthalmology 2010:4
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and possibly ongoing, response to treatment. Only eyes that 
experienced no further improvement or worsening after an 
initial favorable response were retreated.
In addition, treatment strategies used in ranibizumab15 
trials with monthly injections do not necessarily apply to 
bevacizumab. The half-life of intravitreal bevacizumab is 
thought to be about twice that of ranibizumab.16 Mordenti 
and colleagues17 reported that the vitreous half life of a 
recombinant human monoclonal antibody rhuMAB HER2 
(trastuzumab; Genentech), which is a molecule similar to 
bevacizumab, is 5.6 days. The authors concluded that injec-
tions of the antibody into the vitreous cavity may provide 
adequate concentrations for up to two months.17 Thus, less 
frequent bevacizumab administration may theoretically be 
required over a certain period of time compared to ranibi-
zumab. During the three months follow up in this study, less 
than a fifth of the eyes (five eyes, 17.2%) required repeat 
injections, with only three eyes (10.3%) requiring retreatment 
at eight weeks and none at four weeks. This suggests that 
monthly injections may not be necessary and that treatment 
effect appears to be maintained for at least eight weeks in the 
majority of cases. While it is possible that we inadvertently 
selected a group of 29 eyes that happened to be exceptional 
responders to bevacizumab, the fact that our findings are com-
parable to those reported by other investigators9,12,13 suggests 
that a less frequent dosing regimen may be as effective as 
monthly injections. Less frequent administration may greatly 
impact the United States health care system expenditure for 
AMD care, in addition to reducing the risk of intraocular 
infection inherent with each injection.
On the other hand, a potential downside related to a lon-
ger half-life is longer than desired duration of action in the 
case of ocular or systemic toxicity. While the systemic use 
of bevacizumab has been associated with an increased risk 
Figure 4 Fundus photos (left column), late fluorescein angiography frames (middle column) and optical coherence tomography (OCT; right column, same orientation scan in 
all three images) at presentation (upper row), eight weeks (middle row) and 12 weeks follow up (lower row) of the right eye of a patient with good response to bevacizumab. 
Following only one injection of bevacizumab, best-corrected visual acuity (VA) and central macular thickness (CMT; in microns) improved from 20/667 and 420 microns at 
presentation to 20/25 and 208 microns and to 20/60 and 307 microns at eight and 12 weeks, respectively.
Notes: Note absence of leakage on angiography with total resolution of intra-and-subretinal fluid on OCT by eight weeks following a single injection of bevacizumab. Retreat-
ment was performed at 12 weeks because of worsening vision, active leakage along the superior border of the neovascular lesion and increased CMT (third row).
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Figure  5  Change  in  average  central  macular  thickness  (microns)  over  time  as  measured  by  optical  coherence  tomography  (OCT)  following  initial  treatment  with 
  bevacizumab.
Notes: The majority of the change occurred in the first two weeks following treatment with stabilization afterwards. P values at each follow-up visit were obtained by 
  comparing with baseline (P value less than 0.05 indicates statistical significance).
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Figure 6 Number of eyes that required repeat bevacizumab injections during the three-month follow-up period.
Note: Only five out of 29 eyes required repeat injections.Clinical Ophthalmology 2010:4
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of gastrointestinal bleeding, thromboembolic phenomena 
and hypertension,3 particularly in patients with cancer,4 no 
significant ocular or systemic effects have been reported 
with its intravitreal use to date.9–13 Out of all previous studies, 
only Spaide and colleagues11 reported that three (1.2%) out of 
251 patients developed mild vitritis following treatment, one 
patient had a nonfatal myocardial infarction, two patients had 
transient ischemic attacks, and two patients died while under 
treatment with bevacizumab. However, the authors concluded 
that the risk of intraocular inflammation appears to be less than 
that observed in the pegaptanib and ranibizumab trials (about 
16%), and that the risk for thromboembolic disorders did 
not seem to be different than reported in previous studies on 
AMD. This observed short-term safety profile for intravitreal 
as compared to intravenous bevacizumab may be related to the 
localized nature of intraocular injections and the much smaller 
intravitreal dose (1.25–2.50 mg, about 400 times smaller than 
the intravenous dose used for neovascular AMD3). The safety 
profile of intraocular bevacizumab has been recently empha-
sized in the international intravitreal bevacizumab safety 
survey where over a mean follow up of 3.5 months none of the 
adverse event rates exceeded 0.21%.18 While the overall safety 
profile of both intravitreal bevacizumab and ranibizumab has 
been established, Klettner and colleagues19 have recently noted 
that bevacizumab, and not ranibizumab, accumulates in RPE 
cells over time, suggesting that differences in their molecular 
structure and cellular interactions may prove clinically sig-
nificant over time.
While the results of this study are encouraging, several 
shortcomings are worth mentioning. These include the 
retrospective design with varying baseline characteristics 
of included eyes, short-term follow up, small number of 
patients, lack of a control group, nonstandardized visual 
acuity testing, variability in prebevacizumab treatment, 
absence of defined inclusion and exclusion criteria other 
than subfoveal CNV due to AMD, and variable practice 
patterns by individual physicians involved in the study. Yet 
this short term data suggests that intravitreal bevacizumab 
is a safe and effective treatment for neovascular AMD. It 
also suggests that an injection frequency less than once 
per month may be sufficient since initial treatment effect 
was maintained for at least eight weeks in the majority 
of cases. We believe that an injection interval of eight 
weeks is not only as effective as four weeks, but also safer 
and less expensive. Nonetheless, prospective, controlled 
clinical trials are needed to determine the optimal dosing 
strategy and the long-term safety and efficacy of intravitreal 
  bevacizumab.
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Figure 7 Breakdown of the eyes and the various types of treatment rendered prior to bevacizumab. Twenty of 29 eyes (69.0%) had received prior treatment. The majority of 
eyes received photodynamic therapy prior to bevacizumab.Clinical Ophthalmology 2010:4
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